文献速递淋巴瘤

ZUMA-2研究中KTE-X19治疗复发/难治性套细胞淋巴瘤患者的三年随访结果,包括高危亚组

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
PubMed 文献 · J Clin Oncol · 2022-06-04

ZUMA-2研究报告了KTE-X19治疗复发/难治性套细胞淋巴瘤患者三年随访结果。中位随访35.6个月,全部68例可评估患者客观缓解率91%(95%CI 81.8-96.7),完全缓解率68%(95%CI 55.2-78.5);中位缓解持续时间28.2个月,中位无进展生存期25.8个月,中位总生存期46.6个月;安全性可控。

要点

  • 中位随访35.6个月,全部68例患者客观缓解率91%、完全缓解率68%。
  • 中位缓解持续时间28.2个月、无进展生存期25.8个月、总生存期46.6个月。
  • 预设亚组分析显示,无论既往BTKi暴露或高危特征,缓解率一致。

核心结论

  • KTE-X19在复发/难治性套细胞淋巴瘤患者中诱导持久长期缓解且安全性可控,可能也使高危特征患者获益。

研究设计与样本

  • ZUMA-2研究为关键性研究,纳入接受过1至5线既往治疗(包括既往BTKi暴露)的复发/难治性套细胞淋巴瘤患者,给予单次KTE-X19输注(2×10^6 CAR T细胞/kg),共68例可评估患者。

主要发现

  • 中位随访35.6个月,全部68例可评估患者客观缓解率91%(95%CI 81.8至96.7),完全缓解率68%(95%CI 55.2至78.5)。
  • 中位缓解持续时间28.2个月(95%CI 13.5至47.1),中位无进展生存期25.8个月(95%CI 9.6至47.6),中位总生存期46.6个月(95%CI 24.9至不可估计)。
  • 事后分析显示,按既往BTKi暴露或高危特征划分的预设亚组中,客观缓解率和持续缓解率一致。
  • 探索性分析显示,既往接受苯达莫司汀的患者从KTE-X19获益,但显示出T细胞功能减弱的趋势,且在白细胞分离前6个月内 versus 12个月内接受苯达莫司汀影响更大。
  • 迟发性毒性少见;在更长的随访期间,ZUMA-2中仅3%的治疗中出现的不良事件发生在该随访期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics. METHODS: Patients with relapsed/refractory MCL (one to five prior therapies, including prior BTKi exposure) received a single infusion of KTE-X19 (2 × 106 CAR T cells/kg). RESULTS: After a median follow-up of 35.6 months, the objective response rate among all 68 treated patients was 91% (95% CI, 81.8 to 96.7) with 68% complete responses (95% CI, 55.2 to 78.5); medians for duration of response, progression-free survival, and overall survival were 28.2 months (95% CI, 13.5 to 47.1), 25.8 months (95% CI, 9.6 to 47.6), and 46.6 months (95% CI, 24.9 to not estimable), respectively. Post hoc analyses showed that objective response rates and ongoing response rates were consistent among prespecified subgroups by prior BTKi exposure or high-risk characteristics. In an exploratory analysis, patients with prior bendamustine benefited from KTE-X19, but showed a trend toward attenuated T-cell functionality, with more impact of bendamustine given within 6 versus 12 months of leukapheresis. Late-onset toxicities were infrequent; only 3% of treatment-emergent adverse events of interest in ZUMA-2 occurred during this longer follow-up period. Translational assessments revealed associations with long-term benefits of KTE-X19 including high-peak CAR T-cell expansion in responders and the predictive value of minimal residual disease for relapse. CONCLUSION: These data, representing the longest follow-up of CAR T-cell therapy in patients with MCL to date, suggest that KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL and may also benefit those with high-risk characteristics.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wang M, Munoz J, Goy A, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2022. PMID: 35658525. doi:10.1200/JCO.21.02370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。